Alisa Pankki Oyj : No turn-around in sight
Entry price | Target | Stop-loss | Potential |
---|
€19.6 |
€23 |
€17.3 |
+17.35% |
---|
Evli Pankki Oyj's shares display attractive technical aspects to anticipate a comeback of the underlying trend.
Strengths●
● The group's activity appears highly profitable thanks to its outperforming net margins.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● This company will be of major interest to investors in search of a high dividend stock.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
●
●
● The group usually releases upbeat results with huge surprise rates.
Weaknesses● With an enterprise value anticipated at 4.59 times the sales for the current fiscal year, the company turns out to be overvalued.
●
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.